Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 01:44:06 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:DR MARTIN SCURR: How losing your hearing may cause dementia
Next:Storms damage homes in Oklahoma and Kansas. But in Houston, most power is restored
You may also like
- How Robert F. Kennedy Jr. could make the first debate stage
- During the 2023 National Day and Mid
- Xi Meets Blinken in Beijing
- Over 600 enterprises sign up for 7th CIIE
- Mohammad Mokhber: Who is Iran’s acting president?
- Reading This Book to Understand China in the New Era
- Xi Extends Condolences to Indian President, PM over Deadly Train Accident
- Chinese sightseers flock to Tianshui as spicy hot pot goes viral
- Celebrity birthdays for the week of May 26